Auxly Cannabis Group Past Earnings Performance
Past criteria checks 0/6
Auxly Cannabis Group has been growing earnings at an average annual rate of 8.6%, while the Pharmaceuticals industry saw earnings growing at 48.2% annually. Revenues have been growing at an average rate of 34.8% per year.
Key information
8.6%
Earnings growth rate
20.5%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | 34.8% |
Return on equity | -42.7% |
Net Margin | -41.5% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Auxly Cannabis Group Inc.'s (TSE:XLY) Shares Leap 60% Yet They're Still Not Telling The Full Story
Aug 09Market Cool On Auxly Cannabis Group Inc.'s (TSE:XLY) Revenues Pushing Shares 40% Lower
Jun 19Does Auxly Cannabis Group (TSE:XLY) Have A Healthy Balance Sheet?
Apr 27A Piece Of The Puzzle Missing From Auxly Cannabis Group Inc.'s (TSE:XLY) 33% Share Price Climb
Mar 21Auxly Cannabis Group Inc. (TSE:XLY) Stock Rockets 33% But Many Are Still Ignoring The Company
Feb 03Take Care Before Jumping Onto Auxly Cannabis Group Inc. (TSE:XLY) Even Though It's 38% Cheaper
Dec 19Does Auxly Cannabis Group (TSE:XLY) Have A Healthy Balance Sheet?
Oct 17Is Auxly Cannabis Group (TSE:XLY) Using Debt In A Risky Way?
Jul 14Auxly Cannabis Group Inc. (TSE:XLY) Could Be Riskier Than It Looks
Apr 17The Consensus EPS Estimates For Auxly Cannabis Group Inc. (TSE:XLY) Just Fell Dramatically
Aug 11Health Check: How Prudently Does Auxly Cannabis Group (TSE:XLY) Use Debt?
Jul 21Growth Investors: Industry Analysts Just Upgraded Their Auxly Cannabis Group Inc. (TSE:XLY) Revenue Forecasts By 8.2%
Aug 18Auxly Cannabis Group Inc. (TSE:XLY) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 29Breakeven On The Horizon For Auxly Cannabis Group Inc. (CVE:XLY)
Mar 24A Look At Auxly Cannabis Group's (CVE:XLY) Share Price Returns
Jan 28Revenue & Expenses Breakdown
How Auxly Cannabis Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 110 | -45 | 41 | 0 |
31 Mar 24 | 102 | -60 | 40 | 0 |
31 Dec 23 | 101 | -45 | 40 | 0 |
30 Sep 23 | 99 | -7 | 40 | 0 |
30 Jun 23 | 90 | -99 | 42 | 0 |
31 Mar 23 | 96 | -101 | 48 | 0 |
31 Dec 22 | 94 | -130 | 51 | 0 |
30 Sep 22 | 99 | -133 | 54 | 0 |
30 Jun 22 | 104 | -86 | 53 | 0 |
31 Mar 22 | 97 | -75 | 49 | 0 |
31 Dec 21 | 84 | -46 | 46 | 0 |
30 Sep 21 | 73 | -53 | 42 | 0 |
30 Jun 21 | 61 | -57 | 42 | 0 |
31 Mar 21 | 46 | -81 | 42 | 0 |
31 Dec 20 | 47 | -84 | 47 | 0 |
30 Sep 20 | 32 | -116 | 49 | 0 |
30 Jun 20 | 21 | -115 | 54 | 0 |
31 Mar 20 | 17 | -102 | 53 | 0 |
31 Dec 19 | 8 | -103 | 50 | 0 |
30 Sep 19 | 5 | -80 | 53 | 0 |
30 Jun 19 | 4 | -72 | 52 | 0 |
31 Mar 19 | 1 | -70 | 52 | 0 |
31 Dec 18 | 1 | -67 | 48 | 0 |
30 Sep 18 | 2 | -41 | 44 | 0 |
30 Jun 18 | 2 | -38 | 33 | 0 |
31 Mar 18 | 3 | -27 | 24 | 0 |
31 Dec 17 | 2 | -18 | 18 | 0 |
30 Sep 17 | 0 | -9 | 8 | 0 |
30 Jun 17 | 0 | -3 | 4 | 0 |
31 Mar 17 | 0 | -2 | 2 | 0 |
31 Dec 16 | 0 | 0 | 1 | 0 |
30 Sep 16 | 0 | 0 | 0 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
31 Mar 16 | 0 | 0 | 0 | 0 |
31 Dec 15 | 0 | 0 | 0 | 0 |
30 Sep 15 | 0 | 0 | 0 | 0 |
30 Jun 15 | 0 | 0 | 0 | 0 |
31 Mar 15 | 0 | 0 | 0 | 0 |
31 Dec 14 | 0 | 0 | 0 | 0 |
30 Sep 14 | 0 | 0 | 0 | 0 |
30 Jun 14 | 0 | 0 | 0 | 0 |
31 Mar 14 | 0 | 0 | 0 | 0 |
31 Dec 13 | 0 | 0 | 0 | 0 |
30 Sep 13 | 0 | 0 | 0 | 0 |
Quality Earnings: XLY is currently unprofitable.
Growing Profit Margin: XLY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XLY is unprofitable, but has reduced losses over the past 5 years at a rate of 8.6% per year.
Accelerating Growth: Unable to compare XLY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XLY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Return on Equity
High ROE: XLY has a negative Return on Equity (-42.72%), as it is currently unprofitable.